针对主观认知衰退或轻度认知障碍 (APPLE-Tree) 的远程,低强度,多领域的生活方式干预:多中心,单面罩,随机对照试验
Harriet Demnitz-King1, Mariam Adeleke2, Julie A Barber2
1Centre for Psychiatry and Mental Health, Wolfson Institute of Population Health, Queen Mary University London, London, UK.
The lancet. Healthy longevity
|October 23, 2025
概括
果树项目在有记忆问题的成年人中显示出微小的认知改善,尽管在统计学上并不显著. 这种低强度的远程干预为广泛的痴呆症预防策略提供了潜力.
科学领域:
- 老年学是一门学科.
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 高强度干预可以通过改变生活方式和心理因素来减缓认知衰退.
- 患有主观认知衰退或轻度认知障碍的成年人有痴呆症的风险.
- 评估低强度,个性化的痴呆症预防计划至关重要.
研究的目的:
- 评估个性化,低强度痴呆症预防计划的有效性.
- 在经历主观认知衰退或轻度认知障碍的老年人中改善认知.
主要方法:
- 一个为期12个月的单面膜多站点随机对照试验 (APPLE-Tree干预与常规护理).
- 干预包括远程视频通话会议,促进健康的生活方式,社会联系和自我管理.
- 主要结局:24个月的神经心理测试电池 (NTB) 评分,根据治疗意图进行分析.
主要成果:
- 746名参与者被随机分配; 635人被纳入初级分析.
- 两组均显示NTB平均得分增加,而果树组的改善略大 (调整后的平均差异为0.06;p=0.055).
- 没有报告与干预相关的严重不良事件.
结论:
- 果树干预表明,在有记忆问题的成年人中,可能会出现适度的认知改善.
- 可访问,低强度,远程干预可以支持大规模的痴呆症预防工作.
- 需要进一步的研究,以优化日常临床环境的干预措施.
更多相关视频
11:21Methodology for Establishing a Community-Wide Life Laboratory for Capturing Unobtrusive and Continuous Remote Activity and Health Data
Published on: July 27, 2018
8.6K
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.7K
相关概念视频
Cognitive Development During Adulthood
770
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
770
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811
